Results 81 to 90 of about 1,432,292 (149)

Effectiveness and Predictors of House Dust Mite Subcutaneous Immunotherapy in Polysensitised Patients With Allergic Rhinitis: A Multicentre Retrospective Study

Clinical &Experimental Allergy, Volume 56, Issue 6, Page 629-638, June 2026.
Single‐allergen dust mite subcutaneous immunotherapy achieved 68.8% perennial symptom response rate in polysensitised allergic rhinitis patients. High mould and dust mite sIgE levels predicted poor allergen immunotherapy response, which indicated allergen‐specific sIgE levels may help guide personalised allergen immunotherapy decisions.
Zhouxian Pan, Shengyang Yao, Lisha Li, Yongshi Yang, Wenchao Guan, Yin Wang, Xiaoshang Lou, Chuanhe Liu, Yanmin Bao, Shijie Zhuang, Li Sha, Ruonan Chai, Rongfei Zhu, Kai Guan   +13 more
wiley   +1 more source

Changes in the Quality of Life and Symptom Severity in Japanese Cedar Pollinosis Patients at the Time Increase in Cedar Pollen Dispersal [PDF]

The aims of this study were to confirm the relationship between the cumulative exposure level to cedar pollen and the quality of life(QOL)and symptom severity among patients of Japanese cedar pollinosis,and to evaluate the effects of prophylactic ...
MOTOHASHI, Yutaka, SASAJIMA, Hajime, KANEKO, Yoshihiro   +2 more
core   +2 more sources

Current status of sublingual immunotherapy for allergic rhinitis in Japan

Allergology International, 2018
Japanese cedar pollen (JCP) and house dust mite (HDM) are two major allergens that cause allergic rhinitis (AR) in Japan and the prevalence of AR is increasing.
Keisuke Masuyama, Tomokazu Matsuoka, Atsushi Kamijo   +2 more
doaj   +1 more source

Chinese Position Paper on Biologic Therapy for Allergic Rhinitis

Allergy, Volume 81, Issue 5, Page 1354-1369, May 2026.
ABSTRACT Allergic rhinitis (AR) is a common, persistent nasal disorder that poses significant public health challenges worldwide. Current treatment options frequently fail to achieve adequate symptom control in a substantial subset of patients. Over the past two decades, biologic therapies that target type 2 inflammatory pathways have been used to ...
Yuan Zhang, Jingyun Li, Xian Li, Menglin Wang, Xiangli Yang, Li Shi, Zhiwei Cao, Yan Feng, Weiwei Liu, Zhendong Xu, Ruixia Ma, Xiaoping Gao, Wen Liu, Jinmei Xue, Xiaoyong Ren, Xuezhong Li, Xicheng Song, Yi Yang, Fang Quan, Lei Cheng, Weihong Jiang, Huabin Li, Jian Li, Huanhai Liu, Jianfeng Liu, Zheng Liu, Wei Lv, Qianhui Qiu, Xiangdong Wang, Yu Xu, Yuanteng Xu, Qintai Yang, Yucheng Yang, Jing Ye, Hongmeng Yu, Dongdong Zhu, Chengshuo Wang, Luo Zhang   +37 more
wiley   +1 more source

Safety evaluation of the food enzyme containing endo‐polygalacturonase and pectinesterase activities from the non‐genetically modified Aspergillus luchuensis strain GSP‐4‐404

EFSA Journal, Volume 24, Issue 5, May 2026.
Abstract The food enzyme containing endo‐polygalacturonase (1,4‐α‐d‐galacturonan glycanohydrolase; EC 3.2.1.15) and pectinesterase (pectin pectylhydrolase; EC 3.1.1.11) activities is produced with the non‐genetically modified Aspergillus luchuensis strain GSP‐4‐404 by Shin Nihon Chemical Co., Ltd.
EFSA Panel on Food Enzymes (FEZ), Holger Zorn, José Manuel Barat Baviera, Claudia Bolognesi, Francesco Catania, Gabriele Gadermaier, Ralf Greiner, Alicja Mortensen, Yrjö Henrik Roos, Marize Solano, Henk Van Loveren, Laurence Vernis, Magdalena Andryszkiewicz, Daniele Cavanna, Ana Criado, Cristina Fernandes Fraguas, Yi Liu   +16 more
wiley   +1 more source

Enhanced Production of IgE Anti-Japanese Cedar Pollen Specific Antibodies by Peripheral Blood B Cells from Patients with Japanese Cedar Pollinosis [PDF]

, 2008
BackgroundIgE antibodies against Japanese cedar pollen (JCP) play an important role for the pathogenesis of the cedar pollinosis, but the mechanism of their production has been unclear. We explored the capacity of peripheral blood B cells from pollinosis
Hirohata, Shunsei, Nobuharu Ohshima, Ohshima, Nobuharu, Shunsei Hirohata   +3 more
core   +1 more source

Anti-IgE Antibody Therapy for Japanese Cedar Pollinosis: Omalizumab Update

Allergology International, 2008
Seasonal allergic rhinitis (SAR) induced by Japanese cedar pollens is a substantial problem in Japan. Omalizumab, a novel humanized monoclonal anti-immunoglobulin E (IgE) antibody, has already been proven to reduce symptoms associated with SAR.
Kimihiro Okubo, Toshikazu Nagakura
doaj   +1 more source

Greater climate change adaptation potential in populations of Quercus macrocarpa at edges of latitudinal gradient

New Phytologist, Volume 250, Issue 2, Page 1313-1329, April 2026.
Summary With current climate trajectories, tree populations will encounter novel selection pressures that risk local extinction if they are unable to acclimate or adapt. Within a reciprocal transplant experiment with Quercus macrocarpa L. established across a latitudinal gradient, we asked: (1) Is there genetic variation within populations?
Lucy M. S. Rea, Laura Ostrowsky, Rebekah A. Mohn, Mira Garner, Lindsey Worcester, Cathleen Lapadat, Heather R. McCarthy, Andrew L. Hipp, Jeannine Cavender Bares   +8 more
wiley   +1 more source

Reduction of Cedar Pollen Adhesion by Lecithin Polymer Coating [PDF]

, 2005
BackgroundAvoidance of allergens is one of the most effective treatments of allergenic diseases, including pollinosis. Although various masks and goggles for pollinosis sufferers are commercially available, little work has been done on preventing ...
Miyazawa, Kazuyuki, Kohno, Yoshiyuki, Suda, Yukimitsu, Sakuma, Kenichi, Hosoi, Junichi, Kazuyuki Miyazawa, Kenichi Sakuma, Ichikawa, Hideyuki, Maeno, Katsuyuki, Yukimitsu Suda, Yusuke Kobayashi, Kobayashi, Yusuke, Hideyuki Ichikawa, Yoshiyuki Kohno, Junichi Hosoi, Katsuyuki Maeno   +15 more
core   +1 more source

Transcutaneous Delivery of Immunomodulating Pollen Extract-Galactomannan Conjugate by Solid-in-Oil Nanodispersions for Pollinosis Immunotherapy

Pharmaceutics, 2019
Japanese cedar pollinosis is a type I allergic disease and has already become a major public health problem in Japan. Conventional subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) cannot meet patients’ needs owing to the side ...
Qingliang Kong, Kouki Higasijima, Rie Wakabayashi, Yoshiro Tahara, Momoko Kitaoka, Hiroki Obayashi, Yanting Hou, Noriho Kamiya, Masahiro Goto   +8 more
doaj   +1 more source